GSK cancer treatment meets trial endpoint

GSK on Friday unveiled positive headline results from a Phase 3 trial of its Jemperli endometrial cancer drug.

The company said Jemperli met its primary endpoint of investigator-assessed progression-free survival (PFS) and showed a “statistically significant and clinically meaningful benefit”.

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. It is the most common gynaecologic cancer in the US and the second most common gynaecologic cancer globally.

Approximately 15-20% of women with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.

Reporting by Frank Prenesti for Sharecast.com